ARQ 197 and Erlotinib + Placebo and Erlotinib
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small-cell Lung Cancer
Conditions
Non-small-cell Lung Cancer
Trial Timeline
Jul 1, 2011 → —
NCT ID
NCT01377376About ARQ 197 and Erlotinib + Placebo and Erlotinib
ARQ 197 and Erlotinib + Placebo and Erlotinib is a phase 3 stage product being developed by Kyowa Kirin for Non-small-cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01377376. Target conditions include Non-small-cell Lung Cancer.
What happened to similar drugs?
7 of 20 similar drugs in Non-small-cell Lung Cancer were approved
Approved (7) Terminated (5) Active (10)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01377376 | Phase 3 | Terminated |
Competing Products
20 competing products in Non-small-cell Lung Cancer